Mesoblast (MESO) Competitors

Mesoblast (NASDAQ:MESO) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations.

Is MESO or TGTX more profitable?

Mesoblast has a net margin of 0.00% compared to TG Therapeutics' net margin of -5.42%. Mesoblast's return on equity of 0.00% beat TG Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
TG Therapeutics	-5.42%	-8.32%	-3.40%

Which has preferable earnings & valuation, MESO or TGTX?

TG Therapeutics has higher revenue and earnings than Mesoblast.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$5.90M	234.08	-$87.96M	N/A	N/A
TG Therapeutics	$264.79M	20.22	$12.67M	-$0.10	-344.00

Does the MarketBeat Community prefer MESO or TGTX?

TG Therapeutics received 248 more outperform votes than Mesoblast when rated by MarketBeat users. Likewise, 76.57% of users gave TG Therapeutics an outperform vote while only 70.27% of users gave Mesoblast an outperform vote.

Company	Underperform	Outperform
Mesoblast	Outperform Votes 409 70.27%	Underperform Votes 173 29.73%
TG Therapeutics	Outperform Votes 657 76.57%	Underperform Votes 201 23.43%

Do institutionals and insiders hold more shares of MESO or TGTX?

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 10.5% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Do analysts rate MESO or TGTX?

Mesoblast currently has a consensus price target of $11.50, indicating a potential downside of 4.96%. TG Therapeutics has a consensus price target of $40.67, indicating a potential upside of 18.22%. Given TG Therapeutics' higher probable upside, analysts plainly believe TG Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
TG Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Which has more volatility and risk, MESO or TGTX?

Mesoblast has a beta of 3.54, indicating that its stock price is 254% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500.

Does the media prefer MESO or TGTX?

In the previous week, TG Therapeutics had 3 more articles in the media than Mesoblast. MarketBeat recorded 6 mentions for TG Therapeutics and 3 mentions for Mesoblast. TG Therapeutics' average media sentiment score of 1.31 beat Mesoblast's score of 1.04 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Mesoblast on 9 of the 16 factors compared between the two stocks.